Optic Atrophy: Clinical Trials

74 trials for Optic Atrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 completed, 13 recruiting, 9 unknown, 6 active not recruiting. 26 Phase 2, 16 Phase 1, 12 Phase 3, 8 Not applicable, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 226Completed 8, Unknown 7, Active not recruiting 4, Terminated 4, Recruiting 3
Phase 116Completed 6, Terminated 3, Active not recruiting 2, Recruiting 2, Unknown 2, Not yet recruiting 1
Phase 312Completed 5, Active not recruiting 2, Recruiting 2, Unknown 2, Withdrawn 1
Not applicable8Completed 3, Recruiting 3, Unknown 1, Withdrawn 1
Phase 41Completed 1

Follow Optic Atrophy: new trials by email Literature Review of Optic Atrophy trials Research Report on Optic Atrophy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Longitudinal Natural History Study of OPA1-Associated Autosomal-Dominant Optic Atrophy
OPA1 Gene Mutation, Optic Atrophy, Autosomal Dominant
RecruitingLudwig-Maximilians - University of Munich502026-07-162026-07-28
Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy
Nicotinamide treatment - Leber Hereditary Optic Neuropathy (LHON), Leber's Hereditary Optic Neuropathy (LHON)
Phase 1Not yet recruitingUniversity Hospital, Angers132026-04-012025-12-18
Does Recessive Optic Atrophy Due to WFS1 Exist?
analyse study - Wolfram Syndrome 1, Optic Atrophies, Hereditary
Not yet recruitingHôpital Necker-Enfants Malades452026-02-012026-01-13
Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients
GS010 High dose, GS010 Low dose - Leber Hereditary Optic Disease
Phase 2RecruitingGenSight Biologics142026-01-222026-03-02
Mechanisms of Fecal Incontinence in Wolfram Syndrome
Retrospective case-control analysis - Wolfram Syndrome, Fecal Incontinence
Not yet recruitingHôpital Necker-Enfants Malades202025-12-202025-12-31
Optic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center Study
Neuro-Ophthalmology, Optic Neuropathies
Not yet recruitingBarboni702025-10-012025-07-20
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy
Phase 1 / Phase 2RecruitingPYC Therapeutics242025-09-302026-06-29
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness
Phase 3RecruitingLaboratoires Thea322025-06-042026-10-21
SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)
PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy
Phase 1Active not recruitingPYC Therapeutics182024-10-312026-09-17
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
rAAV2-ND4, Sham (No Treatment) - Leber Hereditary Optic Neuropathy (LHON)
Phase 3Active not recruitingWuhan Neurophth Biotechnology Limited Company952024-09-192026-02-12
Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant
TerminatedPYC Therapeutics12024-02-282025-03-14
Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1
Tirzepatide - Wolfram Syndrome
Phase 2UnknownOspedale San Raffaele102024-01-012024-02-22
Building Research With Artificial Intelligence in Neuro-Ophthalmology
Deep learning algorithm applied on retrospectively collected color fundus photographs - Optic Neuropathy, Optic Neuropathy, Ischemic
CompletedFondation Ophtalmologique Adolphe de Rothschild6932023-10-012025-09-08
Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations
NFS-02 Injection - Leber Hereditary Optic Neuropathy (LHON)
Phase 1 / Phase 2TerminatedNeurophth Therapeutics Inc112023-08-152024-09-20
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
CHF6467, Placebo - Optic Pathway Glioma
Phase 2Active not recruitingBenedetto Falsini362023-06-122026-03-19
Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations
NR082 Injection, Injection needle - Leber Hereditary Optic Neuropathy (LHON)
Phase 1 / Phase 2Active not recruitingNeurophth Therapeutics Inc122023-05-222024-09-04
Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)
Optical coherent tomography - Healthy Subjects, Leber Hereditary Optic Neuropathy
Not applicableRecruitingHôpital Necker-Enfants Malades902023-03-102025-11-18
AMX0035 in Adult Patients With Wolfram Syndrome
AMX0035 - Wolfram Syndrome
Phase 2Active not recruitingAmylyx Pharmaceuticals Inc.122023-03-032026-04-14
Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection
Leber's Hereditary Optic Neuropathy (LHON)
CompletedArgo Sante122022-08-042024-02-06
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes - Eye Diseases, Retinitis Pigmentosa
Phase 1RecruitingThe Foundation for Orthopaedics and Regenerative Medicine202022-02-012026-10-16

Showing 20 of 74. Sign in to see all of them.

Narrower conditions

Optic Atrophy, Hereditary, Leber (44)  ·  Eye Diseases (13)  ·  Mitochondrial Diseases (13)  ·  Wolfram Syndrome (12)  ·  Eye Diseases, Hereditary (9)  ·  Diabetes Mellitus (8)  ·  Optic Atrophy, Autosomal Dominant (8)  ·  Optic Nerve Diseases (8)  ·  Optic Neuropathy, Ischemic (7)  ·  Retinitis Pigmentosa (7)  ·  Genetic Diseases, Inborn (6)  ·  Neurodegenerative Diseases (6)  ·  Retinal Diseases (6)  ·  Nervous System Diseases (5)

Broader conditions

Cranial Nerve Diseases (74)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (69)  ·  Nervous System Diseases (69)  ·  Metabolic Diseases (66)  ·  Nutritional and Metabolic Diseases (66)  ·  Optic Nerve Diseases (66)  ·  Heredodegenerative Disorders, Nervous System (64)  ·  Genetic Diseases, Inborn (63)  ·  Eye Diseases (61)  ·  Neurodegenerative Diseases (60)  ·  Eye Diseases, Hereditary (58)  ·  Optic Atrophies, Hereditary (58)  ·  Mitochondrial Diseases (40)  ·  Congenital Abnormalities (19)

Interventions

idebenone (5)  ·  salicylhydroxamic acid (3)  ·  Cysteamine (2)  ·  Valproic Acid (2)  ·  4-phenylbutyric acid (1)  ·  Acetylcysteine (1)  ·  Curcumin (1)  ·  Cyclosporine (1)  ·  Dantrolene (1)  ·  Deferiprone (1)  ·  Exenatide (1)  ·  Immunoglobulins, Intravenous (1)  ·  Jupiter (1)  ·  Lipectomy (1)  ·  Magnetic Resonance Imaging (1)

Sponsors

GenSight Biologics (8)  ·  Santhera Pharmaceuticals (8)  ·  Washington University School of Medicine (4)  ·  Hôpital Necker-Enfants Malades (3)  ·  Laboratoires Thea (3)  ·  PYC Therapeutics (3)  ·  Amgen (2)  ·  Hadassah Medical Organization (2)  ·  MD Stem Cells (2)  ·  Neurophth Therapeutics Inc (2)  ·  State University of New York at Buffalo (2)  ·  University Hospital, Angers (2)  ·  Wuhan Neurophth Biotechnology Limited Company (2)  ·  Alexandria University (1)  ·  Amylyx Pharmaceuticals Inc. (1)

Countries

United States (34)  ·  France (22)  ·  Germany (12)  ·  Italy (12)  ·  United Kingdom (12)  ·  Belgium (8)  ·  Canada (6)  ·  China (6)  ·  Spain (6)  ·  Australia (5)  ·  Netherlands (5)  ·  Austria (4)  ·  Brazil (2)  ·  Denmark (2)  ·  Greece (2)

Top investigators

Jeffrey Weiss, MD (2)  ·  Nancy Newman, MD (2)  ·  Steven Levy, MD (2)  ·  Taosheng Huang (2)  ·  Aishwarya Kundu (1)  ·  Alfredo Sadun, MD, PhD (1)  ·  Alina K Drakon, MD (1)  ·  Benedetto Falsini, MD (1)  ·  Bin Li, MD (1)  ·  Bin Li, PhD,MD (1)  ·  Byron Lam, MD (1)  ·  Byron R Lam, MD (1)

Results publications

PMID 36449262, PMID 34108929, PMID 26199618, PMID 26604914, PMID 26606867, PMID 26892229, PMID 27857759, PMID 27904503, PMID 1463007, PMID 1674640, PMID 18441370, PMID 18441371, PMID 18774912, PMID 1928099, PMID 21343523, PMID 21444653, PMID 21467183, PMID 21788663, PMID 22612072, PMID 22644094, PMID 23049087, PMID 23063736, PMID 23263355, PMID 23388409, PMID 24396955, PMID 24398093, PMID 24457989, PMID 25186535, PMID 25342621, PMID 25408174, PMID 25950380, PMID 26025012, PMID 26742931, PMID 26767384, PMID 27386292, PMID 27426279, PMID 27459537, PMID 27631475, PMID 27749593, PMID 28647203, PMID 29270420, PMID 29454364, PMID 30050918, PMID 30194931, PMID 30559420, PMID 30878986, PMID 31119146, PMID 31215818, PMID 31237206, PMID 31620478

NIH funding

2017 (3), 2015 (2), 2018 (2), 2025 (1), R01DK132090 (1), R01HD070855 (1), R21DK113487 (1), U10EY023558 (1), U54NS078059 (1)